Osteoporosis medication prescribing in British Columbia and Ontario: impact of public drug coverage

@inproceedings{Cadarette2011OsteoporosisMP,
  title={Osteoporosis medication prescribing in British Columbia and Ontario: impact of public drug coverage},
  author={Suzanne M Cadarette and Greg A Carney and D. Baek and Nadia Gunraj and John Michael Paterson and Colin R. Dormuth},
  booktitle={Osteoporosis International},
  year={2011}
}
We compared the patterns of osteoporosis medication prescribing between two provinces in Canada with different public drug coverage policies. Oral bisphosphonates were the primary drugs used, yet access to the second-generation oral bisphosphonates (alendronate, risedronate) was limited in one region. Implications of differential access to oral bisphosphonates warrants further study. Approved therapies for treating osteoporosis in Canada include bisphosphonates, calcitonin, denosumab… CONTINUE READING
6 Citations
9 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-9 of 9 references

Scientific Advisory Council of the Osteoporosis Society of Canada

  • JP Brown, RG Josse
  • Can Med Assoc J
  • 2002
1 Excerpt

Clinical practice guidelines for the diagnosis and management of osteoporosis

  • M Mamdani, A Kopp, G Hawker
  • Can Med Assoc J
  • 1996

Similar Papers

Loading similar papers…